SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

$LIFE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $LIFE alert in real time by email
SC 13G/A 1 form819.htm

OMB APPROVAL

OMB Number: 3235-0145

Estimated average burden hours per response ….11

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 6*)

ATYR PHARMA, INC.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

002120202

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

X Rule 13d-1(b)
  Rule 13d-1(c)
  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 
 

 

CUSIP No.: 002120202

1. Names of Reporting Persons
  I.R.S. Identification Nos. of above persons (entities only)
  Federated Hermes, Inc.
2. Check the Appropriate Box if a Member of a Group (See Instructions)
  (a)
  (b)
3. SEC Use Only
4. Citizenship or place of Organization: Pennsylvania

 

Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:  5,231,600
6. Shared Voting Power
7. Sole Dispositive Power:  5,231,600
8. Shared Dispositive Power

 

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  5,231,600
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11. Percent of Class Represented by Amount in Row (9):  18.03%
12. Type of Reporting Person (See Instructions): HC

 

1. Names of Reporting Persons
  I.R.S. Identification Nos. of above persons (entities only)
  Voting Shares Irrevocable Trust
2. Check the Appropriate Box if a Member of a Group (See Instructions)
  (a)
  (b)
3. SEC Use Only
4. Citizenship or place of Organization: Pennsylvania

 

Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:  5,231,600
6. Shared Voting Power
7. Sole Dispositive Power:  5,231,600
8. Shared Dispositive Power

 

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  5,231,600
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11. Percent of Class Represented by Amount in Row (9):  18.03%
12. Type of Reporting Person (See Instructions): OO

 

1. Names of Reporting Persons
  I.R.S. Identification Nos. of above persons (entities only)
  Thomas R. Donahue
2. Check the Appropriate Box if a Member of a Group (See Instructions)
  (a)
  (b)
3. SEC Use Only
4. Citizenship or place of Organization: United States

 

Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
6. Shared Voting Power:  5,231,600
7. Sole Dispositive Power
8. Shared Dispositive Power:  5,231,600

 

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  5,231,600
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11. Percent of Class Represented by Amount in Row (9):  18.03%
12. Type of Reporting Person (See Instructions): IN

 

1. Names of Reporting Persons
  I.R.S. Identification Nos. of above persons (entities only)
  J. Christopher Donahue
2. Check the Appropriate Box if a Member of a Group (See Instructions)
  (a)
  (b)
3. SEC Use Only
4. Citizenship or place of Organization: United States

 

Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
6. Shared Voting Power:  5,231,600
7. Sole Dispositive Power
8. Shared Dispositive Power:  5,231,600

 

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  5,231,600
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11. Percent of Class Represented by Amount in Row (9):  18.03%
12. Type of Reporting Person (See Instructions): IN

 

Item 1.

(a) Name of Issuer
  ATYR PHARMA, INC.
(b) Address of Issuer’s Principal Executive Offices
  3545 John Hopkins Court, Suite 250
  San Diego, CA  92121

Item 2.

(a) Name of Person Filing: Federated Hermes, Inc.
(b) Address Of Principal Business Office or, if none, Residence
  1001 Liberty Avenue, Pittsburgh, PA  15222-3779
(c) Citizenship: Pennsylvania
(d) Title of Class of Securities
  Common Stock
(e) CUSIP Number: 002120202
Item 3.If this statement is filed pursuant to §§240.113d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)   An investment adviser in accordance with §204.13d-1(b)(1)(ii)(E);
(f)   An employee benefit plan or endowment fund in accordance with §240.13d-19b)(1)(ii)(F);
(g) X A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)   Group, in accordance with §240.13d-1(b)(1)(ii)(J).
Item 4.Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

A. Federated Hermes, Inc.
(a) Amount beneficially owned:  5,231,600
(b) Percent of class:  18.03%
(c) Number of shares to which the person has:
  (i) Sole power to vote or to direct the vote:  5,231,600
  (ii) Shared power to vote or to direct the vote:  0
  (iii) Sole power to dispose or to direct the disposition of:  5,231,600  
  (iv) Shared power to dispose or to direct the disposition of:  0

 

B. Voting Shares Irrevocable Trust
(a) Amount beneficially owned:  5,231,600
(b) Percent of class:  18.03%
(c) Number of shares to which the person has:
  (i) Sole power to vote or to direct the vote:  5,231,600
  (ii) Shared power to vote or to direct the vote:  0
  (iii) Sole power to dispose or to direct the disposition of:  5,231,600  
  (iv) Shared power to dispose or to direct the disposition of:  0

 

 

C. Thomas R. Donahue
(a) Amount beneficially owned:  5,231,600
(b) Percent of class:  18.03%
(c) Number of shares to which the person has:
  (i) Sole power to vote or to direct the vote:  0
  (ii) Shared power to vote or to direct the vote:  5,231,600
  (iii) Sole power to dispose or to direct the disposition of:  0
  (iv) Shared power to dispose or to direct the disposition of:  5,231,600  

 

 

D. J. Christopher Donahue
(a) Amount beneficially owned:  5,231,600
(b) Percent of class:  18.03%
(c) Number of shares to which the person has:
  (i) Sole power to vote or to direct the vote:  0
  (ii) Shared power to vote or to direct the vote:  5,231,600
  (iii) Sole power to dispose or to direct the disposition of:  0
  (iv) Shared power to dispose or to direct the disposition of:  5,231,600

 

Instruction: Dissolution of a group requires a response to this item.

Item 5.Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

Instruction: Dissolution of a group requires a response to this item.

Item 6.Ownership of More than Five Percent on Behalf of Another Person. NOT APPLICABLE
Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit “1” Attached
Item 8.Identification and Classification of Members of the Group: NOT APPLICABLE
Item 9.Notice of Dissolution of Group: NOT APPLICABLE
Item 10.Certification
(a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b);
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.
(b) The following certification shall be included if the statement is filed pursuant to §204.13d-1(c):
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 1, 2023
By: /s/J. Christopher Donahue
Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
   
Date: February 1, 2023
By: /s/Thomas R. Donahue
Name/Title Thomas R. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
   
Date: February 1, 2023
By: /s/J. Christopher Donahue
Name/Title J. Christopher Donahue individually and as Trustee of Voting Shares Irrevocable Trust

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See U.S.C. 1001)

 
 

 

EXHIBIT “1”

ITEM 3 CLASSIFICATION OF REPORTING PERSONS

Identity and Classification of Each Reporting Person

 

IDENTITY CLASSIFICATION UNDER ITEM 3
Federated Hermes Equity Funds (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
Federated Hermes Insurance Series (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
Federated Equity Management Company of Pennsylvania (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
Federated Global Investment Management Corp. (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
Federated Hermes, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
FII Holdings, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
Voting Shares Irrevocable Trust (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
Thomas R. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
J. Christopher Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)

Federated Hermes, Inc. (the “Parent”) is filing this schedule 13G because it is the parent holding company of Federated Equity Management Company of Pennsylvania and Federated Global Investment Management Corp. (the “Investment Advisers”), which act as investment advisers to registered investment companies and separate accounts that own shares of common stock in ATYR PHARMA, INC. (the “Reported Securities”). The Investment Advisers are wholly owned subsidiaries of FII Holdings, Inc., which is wholly owned subsidiary of Federated Hermes, Inc., the Parent. All of the Parent’s outstanding voting stock is held in the Voting Shares Irrevocable Trust (the “Trust”) for which Thomas R. Donahue and J. Christopher Donahue act as trustees (collectively, the “Trustees”). The Trustees have joined in filing this Schedule 13G because of the collective voting control that they exercise over the Parent. In accordance with Rule 13d-4 under the Securities Act of 1934, as amended, the Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

 
 

EXHIBIT “2”

AGREEMENT FOR JOINT FILING OF

SCHEDULE 13G

The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934:

1.       Federated Hermes, Inc. as parent holding company of the investment advisers to registered investment companies that beneficially own the securities.

Voting Shares Irrevocable Trust, as holder of all the voting shares of Federated Hermes, Inc.

Thomas R. Donahue, individually and as Trustee

J. Christopher Donahue, individually and as Trustee

It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other parties unless such party knows or has reason to believe that such information is incomplete or inaccurate.

It is understood and agreed that the joint filing of Schedule 13G shall not be construed as an admission that the reporting persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

Date: February 1, 2023

By: /s/J. Christopher Donahue
Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
   
By: /s/Thomas R. Donahue
Name/Title Thomas R. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust.
   
By: /s/J. Christopher Donahue
Name/Title J. Christopher Donahue, individually and as Trustee of Voting Shares Irrevocable Trust

1.       The number of shares indicated represent shares beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc. that have been delegated the power to direct investment and power to vote the securities by the registered investment companies’ board of trustees or directors and by the separate accounts’ principals. All of the voting securities of Federated Hermes, Inc. are held in the Voting Shares Irrevocable Trust (“Trust”), the trustees of which are Thomas R. Donahue and J. Christopher Donahue (“Trustees”). In accordance with Rule 13d-4 under the 1934 Act, the Trust, Trustees, and parent holding company declare that the filing of this statement should not be construed as an admission that any of the investment advisers, parent holding company, Trust, and Trustees are beneficial owners (for the purposes of Sections 13(d) and/or 13(g) of the Act) of any securities covered by this statement, and such advisers, parent holding company, Trust, and Trustees expressly disclaim that they are the beneficial owners of such securities.

 
 

 

EXHIBIT “3”

 

Get the next $LIFE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LIFE

DatePrice TargetRatingAnalyst
7/5/2023Outperform → Perform
Oppenheimer
11/11/2021$18.00 → $11.00Buy
HC Wainwright & Co.
11/11/2021$18.00 → $11.00Action List Buy
HC Wainwright & Co.
10/12/2021$22.00Outperform
RBC Capital
9/21/2021$19.00Overweight
Piper Sandler
9/14/2021$20.00 → $21.00Buy
Roth Capital
9/14/2021$14.00 → $20.00Outperform
Oppenheimer
9/13/2021$13.00 → $18.00Buy
HC Wainwright & Co.
More analyst ratings

$LIFE
Press Releases

Fastest customizable press release news feed in the world

See more
  • aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

    SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the "ATYR" ticker symbol is a strong reflec

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr's common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants. These stock awards were granted as an inducement material

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

    SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. "These findings further demonstrate the unique way in which efzofitimod is modulating myeloid cells to confer the anti-inflammatory benefits we have seen in patients with pulmonary sarcoidosis, a major form o

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$LIFE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LIFE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$LIFE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LIFE
SEC Filings

See more

$LIFE
Leadership Updates

Live Leadership Updates

See more
  • aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

    SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

    NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

    $AMGN
    $APVO
    $BCTX
    $BMY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$LIFE
Financials

Live finance-specific insights

See more
  • aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

    SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$LIFE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more